首页> 美国卫生研究院文献>International Journal of Pharmaceutics: X >Drug crystal growth in ternary amorphous solid dispersions: Effect of surfactants and polymeric matrix-carriers
【2h】

Drug crystal growth in ternary amorphous solid dispersions: Effect of surfactants and polymeric matrix-carriers

机译:三元无定形固体分散体中的药物晶体生长:表面活性剂和聚合物基质 - 载体的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study evaluates the crystal growth rate of amorphous drugs when dispersed in different ternary polymeric amorphous solid dispersions (ASDs) in the presence of surfactants. Specifically, ternary ASDs of aprepitant (APT, selected as a model drug) were prepared via melt-quench cooling by evaluating three commonly used ASDs matrix/carriers, namely hydroxypropyl cellulose (HPC), poly(vinylpyrrolidone) (PVP) and the copolymer Soluplus® (SOL), and two suitable surfactants, namely d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (P407). Results showed that all components were completely miscible (verified via hot stage polarized microscopy) and both surfactants were acting as plasticizers to the API. APT's crystal growth rate was increased in the presence of both P407 and TPGS, while PVP was identified as the matrix/carrier with the greatest impact API's crystal growth rate inhibition. Interestingly, TPGS presented a noticeable synergistic effect when combined with PVP resulting in a further reduction of APT's crystal growth rate. Furthermore, evaluation of APT's nucleation induction time in dissolution medium (PBS pH 6.8) revealed PVP as the most effective crystallization inhibitor, whereas the addition of TPGS showed to improve PVP's ability to inhibit APT's recrystallization. Finally, the formation of intermolecular interactions in the ternary APT-PVP-TPGS provided an explanation for the observed PVP-TPGS synergistic effects, with molecular dynamics simulations being able to unravel the type and extent of these interactions on a theoretical basis.
机译:分散在表面活性剂存在不同的三元聚合物的无定形固体分散体(自闭症)当本研究评估的无定形药物的晶体生长速率。具体而言,通过熔融骤冷通过评估三种常用的ASD基质/载体,即羟丙基纤维素(HPC),聚(乙烯吡咯烷酮)(PVP)和共聚物Soluplus冷却制备阿瑞吡坦的三元的ASD(APT,选择作为模型药物) ®(SOL),和两个合适的表面活性剂,即D-α生育酚聚乙二醇1000琥珀酸酯(TPGS)和聚(乙二醇) - 嵌段 - 聚(丙二醇) - 嵌段 - 聚(乙二醇)(P407)。结果表明,所有组分是完全混溶(通过热台显微偏光认证)和两个表面活性剂作为增塑剂的API。 APT的晶体生长速率在这两个P407和TPGS的存在增加,同时PVP被确定为具有最大影响API的晶体生长率抑制基质/载体中。有趣的是,当与PVP导致进一步降低APT的晶体生长速率的组合TPGS呈现显着的协同效应。此外,在溶出介质(PBS pH6.8)中APT的成核诱导时间评价表明PVP作为最有效的结晶抑制剂,而除了TPGS的显示,以提高PVP的抑制APT的再结晶的能力。最后,分子间相互作用在三元APT-PVP-TPGS形成提供了所观察到的PVP-TPGS协同作用的说明,与分子动力学模拟能够解开这些相互作用的类型和程度的理论的基础上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号